MiniMed Group, Inc. (MMED)
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-09-04
$23.29-2.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · MMED
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive growth by launching and expanding the MiniMed Flex insulin pump in the U.S. and internationally, including regulatory approvals and market coverage expansions.
Stated in 2 of last 2 quarters. The MiniMed Flex insulin pump launch contributed to U.S. net sales growth from $212M in 2025-Q3 to $240M in 2026-Q3 (13.1% growth) and worldwide net sales growth from $723M to $843M (16.6%). Management's statements and revenue growth indicate delivering progress on commercialization.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The U.S. launch of MiniMed Flex is bringing new patients, driving conversions, and generating new account growth.”
“MiniMed Flex received FDA clearance several months earlier than anticipated, facilitating earlier commercialization.”
Focus on reducing operating losses and moving toward profitability through revenue growth and expense management.
Stated in 2 of last 2 quarters. Operating income improved from a loss of $13M in 2025-Q3 to a positive $5M in 2026-Q3, and net income loss narrowed from -$19M in 2025-Q1 to near breakeven in 2026-Q3. This shows delivering progress on managing losses and improving profitability.
“Operating income was $5 million compared to a loss of $13 million in the prior year quarter.”
“Net income loss was $16 million in 2026-Q1, showing ongoing focus on managing losses.”
Ensure smooth executive and board transitions to support stable governance and leadership continuity.
Stated in 3 of last 3 quarters. Management has reported multiple orderly executive and board transitions including General Counsel resignation with planned transition, new independent director appointments, and board reconstitution post-IPO. This indicates consistent focus on governance stability.
“General Counsel resigning with planned transition period, representing a genuine loss but orderly process.”
“Two new independent directors appointed to fill board vacancies after size increase.”
“Board reconstitution following spin-off/IPO with new nine-member board appointed.”
Maintain disciplined capital allocation including credit facilities and equity offerings to support growth and operations.
Stated in 2 of last 2 quarters. Management completed a $560M IPO and established a $500M revolving credit facility in 2026-Q1. These capital structure actions support operational and growth needs, showing delivering on financing arrangements.
“Completed IPO of 28 million shares at $20 per share, transitioning from Medtronic subsidiary.”
“Entered into $500 million senior secured revolving credit facility with Citibank.”
Not investment advice. As of 2026-09-04.